Publications by authors named "Mette Sieg"
Background: With evidence for large nocebo effects in pain, guidelines for nocebo-minimizing strategies regarding side effect disclosure are emerging. While the ethical implications and effectiveness of such strategies have been the subject of investigations, the perspective of healthcare users are missing despite the stakes for patient autonomy.
Methods: In an online survey, 2766 adults (≥18 years) from a general population sample in Europe and North America responded to questions related to nocebo familiarity, nocebo beliefs and attitudes towards side effect disclosure.
Informing patients about potential side effects of pain treatment is a requirement that protects patients and aids decision making, but it increases the likelihood of unwanted nocebo side effects. If patients do not desire all side-effect information, it may be possible to ethically reduce nocebo effects through authorized concealment of side effects, whereby patients and clinicians engage in shared decision-making to regulate the disclosure of side-effect information. Currently, there is no experimental data clarifying the factors that causally influence desire for side-effect information in pain treatment.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the impact of placebo analgesia (pain relief) and nocebo hyperalgesia (pain increase) in patients with mild-to-moderate Alzheimer's disease (AD), which is not well understood.
- Twenty-one AD patients and 26 healthy participants were exposed to thermal pain under different conditions involving lidocaine and capsaicin, with verbal suggestions to influence pain perception.
- Results showed that healthy participants experienced placebo effects, while AD patients did not show significant placebo or nocebo effects, suggesting that AD might limit these phenomena, which is important for clinical trial design and treatment approaches.
Background: The nocebo response refers to the phenomenon where non-specific factors, including negative verbal suggestion and treatment expectations, cause adverse events (AE) following a placebo treatment. Non-specific factors are also likely to influence AE occurrence following administration of active pharmacological treatments.
Objective: This meta-analysis aimed to estimate the nocebo response in dentistry by assessing the AEs prevalence in placebo- and active arms of randomised controlled trials (RCTs) assessing analgesic treatment following third molar (M3) surgery.
Background: Evidence for the nocebo effect, a phenomenon characterised by suboptimal treatment efficacy, worsening of symptoms, or the occurrence of adverse events caused by an individual's negative treatment expectations, is growing across a multitude of medical fields. However, little attention has been paid to patients' negative expectations and the nocebo effect within dentistry.
Aim: This review summarises essential evidence of the nocebo phenomenon especially in relation to pain and drug administration.
Objectives: Previous studies have found little association between objective measures and the subjective experience of opioid-induced constipation. The subjective experience of opioid-induced constipation may be influenced by treatment expectations. While most trials control for treatment expectations through blinding, success rate is generally low.
View Article and Find Full Text PDF